Nonetheless, the clinical benefit observed with pharmacological inhibition suggests that KHK may be a promising therapeutic target for cardiometabolic diseases including NAFLD and type 2 diabetes mellitus. The gene discussed is KHK; the disease is metabolic dysfunction-associated steatotic liver disease.